Pharma M&A Feeding Frenzy Set To Continue As Investors Ask 'Who's Next?'
This article was originally published in Scrip
A decade-long M&A cycle has hit a high point with Pfizer Inc.'s plan to devour Allergan PLC and the consolidation trend looks set to continue amid bullish investor sentiment, with most activity likely to be in the area of mid-sized branded drug makers, analysts say.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.